Lantheus (NASDAQ:LNTH) Stock Rating Lowered by StockNews.com

Lantheus (NASDAQ:LNTH) was downgraded by equities researchers at StockNews.com from a “buy” rating to a “hold” rating in a research note issued on Friday.

A number of other research analysts also recently issued reports on the stock. Truist Financial boosted their target price on shares of Lantheus from $82.00 to $96.00 and gave the company a “buy” rating in a research report on Friday. JMP Securities reissued a “market outperform” rating and issued a $100.00 price objective on shares of Lantheus in a report on Friday, February 23rd. Mizuho raised their target price on Lantheus from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Friday. Finally, B. Riley boosted their price target on Lantheus from $95.00 to $99.00 and gave the company a “buy” rating in a report on Thursday, April 18th. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, Lantheus presently has a consensus rating of “Moderate Buy” and a consensus target price of $103.14.

Lantheus Stock Performance

LNTH stock traded down $2.65 during midday trading on Friday, reaching $75.53. The stock had a trading volume of 1,837,766 shares, compared to its average volume of 1,079,936. The company has a debt-to-equity ratio of 0.69, a quick ratio of 5.45 and a current ratio of 5.80. The firm has a fifty day simple moving average of $62.67 and a two-hundred day simple moving average of $62.83. The stock has a market cap of $5.18 billion, a PE ratio of 16.28 and a beta of 0.52. Lantheus has a 52-week low of $50.20 and a 52-week high of $100.85.

Lantheus (NASDAQ:LNTH) last released its earnings results on Thursday, February 22nd. The medical equipment provider reported $1.59 EPS for the quarter, topping analysts’ consensus estimates of $1.33 by $0.26. Lantheus had a return on equity of 63.16% and a net margin of 25.20%. The firm had revenue of $354.00 million during the quarter, compared to the consensus estimate of $350.44 million. As a group, equities research analysts anticipate that Lantheus will post 5.96 EPS for the current year.

Insider Activity

In related news, major shareholder Lantheus Alpha Therapy, Llc purchased 60,431,039 shares of the business’s stock in a transaction that occurred on Wednesday, March 6th. The stock was bought at an average price of $0.95 per share, with a total value of $57,409,487.05. Following the acquisition, the insider now owns 116,773,394 shares in the company, valued at $110,934,724.30. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, Director Mary Anne Heino sold 93,863 shares of Lantheus stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $65.31, for a total value of $6,130,192.53. Following the sale, the director now directly owns 251,643 shares of the company’s stock, valued at $16,434,804.33. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Lantheus Alpha Therapy, Llc acquired 60,431,039 shares of Lantheus stock in a transaction that occurred on Wednesday, March 6th. The stock was purchased at an average cost of $0.95 per share, with a total value of $57,409,487.05. Following the completion of the purchase, the insider now owns 116,773,394 shares in the company, valued at approximately $110,934,724.30. The disclosure for this purchase can be found here. Insiders have sold 94,545 shares of company stock worth $6,169,936 in the last quarter. Corporate insiders own 1.50% of the company’s stock.

Institutional Investors Weigh In On Lantheus

Large investors have recently modified their holdings of the business. Tucker Asset Management LLC grew its stake in Lantheus by 239.0% during the 3rd quarter. Tucker Asset Management LLC now owns 400 shares of the medical equipment provider’s stock valued at $28,000 after acquiring an additional 282 shares in the last quarter. UMB Bank n.a. increased its holdings in shares of Lantheus by 161.4% in the first quarter. UMB Bank n.a. now owns 400 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 247 shares during the last quarter. First Horizon Advisors Inc. lifted its position in Lantheus by 97.0% during the third quarter. First Horizon Advisors Inc. now owns 457 shares of the medical equipment provider’s stock worth $32,000 after buying an additional 225 shares in the last quarter. Principal Securities Inc. acquired a new position in Lantheus during the fourth quarter worth $28,000. Finally, Covestor Ltd increased its stake in shares of Lantheus by 62.7% in the 3rd quarter. Covestor Ltd now owns 527 shares of the medical equipment provider’s stock worth $37,000 after acquiring an additional 203 shares during the last quarter. Hedge funds and other institutional investors own 99.06% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.